Analysis of gut microbiota in Restless Legs Syndrome: searching for a metagenomic signatureOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study characterized the gut microbiome in Restless Legs Syndrome and tested whether it forms a signature distinct from insomnia and healthy controls. It also linked microbiota to RLS clinical features like severity and disease duration. Fecal microbiota was profiled by 16S rRNA V3-V4 sequencing on the Illumina MiSeq platform. Differential abundance used DESeq2 and Aldex2, correcting for age, sex, body mass index, sequencing run and mood disorders. Validated sleep and depression questionnaires were administered.
Who was studied?
The cohort included 37 patients with idiopathic Restless Legs Syndrome, 31 with chronic insomnia, and 33 healthy controls, recruited at an Italian sleep center between 2022 and 2024. Groups were matched for sex and age. RLS patients averaged 64.8 years, with 28 women, and a mean disease duration of 26 years. Most RLS patients had moderate to severe symptoms. People with acute inflammation, recent antibiotics, pregnancy or major sedative use were excluded.
What were the most important findings?
Two genera, Lachnoclostridium and Flavonifractor, were significantly reduced in Restless Legs Syndrome compared with both controls and insomnia patients. Neither genus was altered in insomnia versus controls, marking an RLS-specific signature. Four further genera trended down in the same direction. The Lachnospiraceae family also trended lower in RLS. Lachnoclostridium fell further in patients with longer disease duration and a predominant motor phenotype. Alpha and beta diversity did not differ between the three groups overall, though diversity rose with longer RLS duration. Several genera correlated with symptom severity and sleep-quality scores.
What are the greatest implications of this study?
As the first microbiome characterization of Restless Legs Syndrome, the study identifies candidate bacterial markers that could support diagnosis and future microbiota-based therapy. The reduced genera produce short-chain fatty acids and modulate inflammation, hinting at a gut-inflammation-dopamine link. Because the signature held after adjusting for gastrointestinal and mood comorbidities, dysbiosis appears to be an independent factor. The cohort was small and ethnically homogeneous, limiting generalizability. The authors call for larger, multi-ethnic studies with metabolomic and inflammatory data.